Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 6/20 | 0.45 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884862 | 0.91 | FPR2 (0.49) | FPR2CALCRLRAMP1MAPTKDM4E | |
| SCHEMBL2604336 | 0.85 | CALCRL (0.58) | CALCRLRAMP1MAPK1NAMPT | |
| SCHEMBL5091149 | 0.84 | GPR119 (0.46) | CALCRLRAMP1CRBNDDB1NAMPT | |
| SCHEMBL3657213 | 0.83 | FPR2 (0.52) | FPR2MAPTKDM4ETHRBTP53 | |
| SCHEMBL30014780 | 0.83 | FPR2 (0.52) | FPR2MAPTKDM4ETHRBTP53 | |
| SCHEMBL24895522 | 0.83 | MAPT (0.48) | FPR2CALCRLRAMP1MAPTKDM4E | |
| SCHEMBL17803177 | 0.81 | BRD4 (0.52) | CTSSBRD4CALCRLRAMP1MAPK1 | |
| SCHEMBL30167475 | 0.81 | FPR2 (0.47) | FPR2CALCRLRAMP1KDM4ECRBN | |
| SCHEMBL3963958 | 0.80 | KDM4E (0.44) | FPR2CALCRLRAMP1MAPTKDM4E | |
| SCHEMBL2709205 | 0.78 | FPR2 (0.51) | FPR2TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001332-B | Piperidine derivatives | 豪夫迈·罗氏有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3227282-A1 | NOVEL PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20050267137-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-12-01 | — | — | US | disclosed |
| EP-1228059-B1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267137-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | CALCRL, CALCA, CALCR | FPR2 293/4885CTSS 768/4885BRD4 3402/4885 |
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | FPR2 684/4885CTSS 2891/4885BRD4 675/4885 |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | CALCA, CALCRL, CALCB | FPR2 268/4885CTSS 889/4885BRD4 3369/4885 |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | FPR2 684/4885CTSS 2891/4885BRD4 675/4885 |
| US-10172843-B2 | Piperidine derivatives | ADRA1D, ADORA1, ADRA1A | FPR2 801/4885CTSS 2938/4885BRD4 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.